Autopsy report · NCT07006311
Robotic-assisted Bronchoscopy Under Moderate Sedation With Propofol
Cause of deathStaffing, sites or logistics
“After enrolment of 10 patients, key study personnel left the institution, making continuation of the study at the current site no longer feasible.”
Life of this trial
- Registered 3 months before it started.
- Ran for about 10 months before it stopped.
- 10 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Na
- Sponsor
- University of Zurich
- Sponsor type
- University, hospital or other
- Conditions
- Lung Lesions; Robotic Assisted Bronchoscopy; Propofol; Bronchoscopy; Bronchoscopy Biopsy
- Interventions
- Robotic-assisted bronchoscopy under propofol
- Participants
- 10
- Sites
- 1
- Countries
- Switzerland
Trials that died the same way
- Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.
“The study was terminated early due to the inability to recruit the planned number of patients” - The Effect on Mucosal Healing With Pentasa Sachet in Mild to Moderate Active "Drug: Crohn's Disease"
“Study terminated due to lack of eligible patients” - The Role of Cerebral Oximetry in Pediatric Concussion Assessment
“Key Personnel Left Institution Prior to Study Completion” - A Study of Mitomycin C, Irinotecan, and Cetuximab
“The study was discontinued due to the death of a co-investigator and a second co-investigator leaving the institution.” - PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)
“The study is terminated because the PI left the institution.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.